Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Profiles
Research units
Equipment
Projects
Research output
Activities
Press/Media
Prizes
Search by expertise, name or affiliation
Trizivir
Philip Keiser, Naiel Nassar
Research output
:
Contribution to journal
›
Article
›
peer-review
3
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Trizivir'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Protease Inhibitors
100%
Human Immunodeficiency Virus Type 1 (HIV-1)
66%
Antiretroviral Therapy
33%
Nucleoside Analogues
33%
Viral Replication
33%
Patient numbers
33%
Nucleosides
33%
Armamentarium
33%
HIV Treatment
33%
Zidovudine
33%
Twice Daily
33%
Alternative Regimens
33%
Protease Inhibitor Therapy
33%
Lamivudine
33%
Indinavir
33%
Dosing Schedule
33%
Pill Burden
33%
Treatment of HIV Infection
33%
Abacavir
33%
Combination Tablet
33%
Plasma RNA
33%
Pharmacology, Toxicology and Pharmaceutical Science
Abacavir Plus Lamivudine Plus Zidovudine
100%
Proteinase Inhibitor
66%
HIV
50%
Toxicity
16%
Side Effect
16%
RNA
16%
Nucleoside Analog
16%
Nucleoside
16%
Human Immunodeficiency Virus Infection
16%
Hyperlipidemia
16%
Allergic Reaction
16%
Tablet
16%
Abacavir
16%
Indinavir
16%
Lamivudine Plus Zidovudine
16%
HIV Therapy
16%
INIS
hiv
100%
therapy
60%
patients
40%
nucleosides
40%
administration
20%
plasma
20%
comparative evaluations
20%
toxicity
20%
side effects
20%
rna
20%
schedules
20%